Literature DB >> 15518041

IP-10 and type 1 diabetes: a question of time and location.

Urs Christen1, Matthias G von Herrath.   

Abstract

Chemokines are key signal molecules that attract cells of the host immune system to the site of a potential threat. Virus infections usually induce a massive chemokine and cytokine burst and therefore recruit a large plethora of leukocytes to the site of infection with the goal to restrict and abrogate viral spread. The down side of this massive excitation of the human defense system is non-specific activation of potentially self-reactive lymphocytes. Coupled with an antigen-specific event, for example molecular mimicry between host components and viral proteins, autoimmunity might be the consequence in susceptible individuals. However, activated immune components with autoaggressive potential must find their target and must remain in one site sufficiently long in order to cause chronic tissue damage. In this review we will focus on the influence of the chemokine IP-10 (CXCL10) on the trafficking of autoaggressive cells during the immunopathogenesis of type 1 diabetes (T1D) and explain why IP-10 can have a dual effect on T1D depending on time and location of expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15518041

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  20 in total

Review 1.  Novel biomarkers in type 1 diabetes.

Authors:  Yulan Jin; Jin-Xiong She
Journal:  Rev Diabet Stud       Date:  2012-12-28

2.  Small molecule CXCR3 antagonist NIBR2130 has only a limited impact on type 1 diabetes in a virus-induced mouse model.

Authors:  S Christen; M Holdener; C Beerli; G Thoma; M Bayer; J M Pfeilschifter; E Hintermann; H-G Zerwes; U Christen
Journal:  Clin Exp Immunol       Date:  2011-06-07       Impact factor: 4.330

3.  Induction of the chemokine interferon-gamma-inducible protein-10 in human pancreatic islets during enterovirus infection.

Authors:  A-K Berg; O Korsgren; G Frisk
Journal:  Diabetologia       Date:  2006-09-13       Impact factor: 10.122

4.  Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus.

Authors:  K O Kong; A W Tan; B Y H Thong; T Y Lian; Y K Cheng; C L Teh; E T Koh; H H Chng; W G Law; T C Lau; K P Leong; B P Leung; H S Howe
Journal:  Clin Exp Immunol       Date:  2009-01-23       Impact factor: 4.330

5.  Biomarkers for type 1 diabetes.

Authors:  Sharad Purohit; Jin-Xiong She
Journal:  Int J Clin Exp Med       Date:  2008-02-29

Review 6.  Endocrine manifestations of hepatitis C virus infection.

Authors:  Alessandro Antonelli; Clodoveo Ferri; Silvia Martina Ferrari; Michele Colaci; Domenico Sansonno; Poupak Fallahi
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2009-01

7.  Altered kinetics of interleukin-6 and other inflammatory mediators during exercise in children with type 1 diabetes.

Authors:  Jaime S Rosa; Stacy R Oliver; Masato Mitsuhashi; Rebecca L Flores; Andria M Pontello; Frank P Zaldivar; Pietro R Galassetti
Journal:  J Investig Med       Date:  2008-04       Impact factor: 2.895

Review 8.  CXCL10 activities, biological structure, and source along with its significant role played in pathophysiology of type I diabetes mellitus.

Authors:  Zahra Ahmadi; Mohammad Kazemi Arababadi; Gholamhossin Hassanshahi
Journal:  Inflammation       Date:  2013-04       Impact factor: 4.092

9.  Enterovirus infection, CXC chemokine ligand 10 (CXCL10), and CXCR3 circuit: a mechanism of accelerated beta-cell failure in fulminant type 1 diabetes.

Authors:  Shoichiro Tanaka; Yoriko Nishida; Kaoru Aida; Taro Maruyama; Akira Shimada; Masako Suzuki; Hiroki Shimura; Soichi Takizawa; Masashi Takahashi; Daiichiro Akiyama; Sayaka Arai-Yamashita; Fumihiko Furuya; Akio Kawaguchi; Masahiro Kaneshige; Ryohei Katoh; Toyoshi Endo; Tetsuro Kobayashi
Journal:  Diabetes       Date:  2009-07-29       Impact factor: 9.461

10.  Interleukin-21 is required for the development of type 1 diabetes in NOD mice.

Authors:  Andrew P R Sutherland; Tom Van Belle; Andrea L Wurster; Akira Suto; Monia Michaud; Dorothy Zhang; Michael J Grusby; Matthias von Herrath
Journal:  Diabetes       Date:  2009-02-10       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.